2018
DOI: 10.1016/j.lfs.2018.08.053
|View full text |Cite
|
Sign up to set email alerts
|

Moderate-intensity exercise and renin angiotensin system blockade improve the renovascular hypertension (2K1C)-induced gastric dysmotility in rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 36 publications
0
7
0
Order By: Relevance
“…We previously showed that 2K1C hypertension increases the gastric retention of a liquid test meal in awake rats, prevented by treatment with aliskiren, captopril or losartan, blockers of renin, angiotensin-converting enzyme (ACE), and ATR 1 , respectively (Lima et al, 2018). We also found that the performance of chronic physical exercise also reverted the 2K1C hypertension-induced gastric emptying delay, in the same way as treatment with these drugs.…”
Section: Introductionmentioning
confidence: 83%
See 1 more Smart Citation
“…We previously showed that 2K1C hypertension increases the gastric retention of a liquid test meal in awake rats, prevented by treatment with aliskiren, captopril or losartan, blockers of renin, angiotensin-converting enzyme (ACE), and ATR 1 , respectively (Lima et al, 2018). We also found that the performance of chronic physical exercise also reverted the 2K1C hypertension-induced gastric emptying delay, in the same way as treatment with these drugs.…”
Section: Introductionmentioning
confidence: 83%
“…Renovascular hypertension (2K1C) was originally designed in dogs by Goldblatt and co-workers (1934), and was later adapted for rats (Lima et al, 2018). After anesthesia with ketamine (80 mg/kg i.m) and xylazine (20 mg/kg, i.m.…”
Section: Induction Of 2k1c Renovascular Hypertensionmentioning
confidence: 99%
“…In in vivo experiments involving awake or freely moving animals, baseline values are used from sham groups, when the animals, in addition to the implantation of electrodes for continuous ECG recording, are also subjected to other surgical procedures as preparation for the further course of the experiment, but without subsequent targeted experimental intervention. For example, preparation for coronary or femoral artery occlusion (Aires et al, 2017; De La Fuente et al, 2013; Nobre et al, 2006), catheterization (Beckers et al, 2006; Blanco et al, 2015; Fiorino et al, 2012; Krüger et al, 1997, 2000; Mostarda et al, 2009; Müller‐Ribeiro et al, 2017; Quagliotto et al, 2015; Ramaekers et al, 2002; Ribeiro et al, 2021; Sallam et al, 2016, 2017; Shi et al, 2020; Simoes et al, 2016), ligation (Lima et al, 2018; Maida et al, 2017; Ruiz et al, 2014; Wang et al, 2016), bile duct ligation (Haddadian et al, 2013), cannulation (Beltrán et al, 2020; Da Silva et al, 2002; Neto et al, 2017; Sant'Ana et al, 2011), implantation of stimulators (Dai et al, 2020; Domingos‐Souza et al, 2021), or if they have already been administered substances beforehand (Lo Giudice et al, 2002).…”
Section: Hrv: Control (Baseline) Values From Frequency‐domain Analysismentioning
confidence: 99%
“…Similar to investigations that analyzed changes in autonomic nervous system activity using frequency‐domain analysis, other studies have used time‐domain analysis of HRV. As in frequency‐domain studies, baseline values not only in sham groups were used (Abulaiti et al, 2011; De La Fuente et al, 2013; Houshmand et al, 2017; Krüger et al, 1997, 2000; Lima et al, 2018; Müller‐Ribeiro et al, 2017; Sallam et al, 2016, 2017; Silva, Geraldini, et al, 2017; Silva, Silva, et al, 2017; Soler et al, 2018; Wang et al, 2016; Xu et al, 2020), but also from groups in which the values were recorded only before the experimental intervention itself and the animals did not undergo surgical preparation (control) (Barbier et al, 2006; Beckers et al, 2006; Beltrán et al, 2020; Couderc et al, 2002; Farraj et al, 2009; Fazan Jr. et al, 2015; Hashimoto et al, 1999; Hazari et al, 2021; Koresh et al, 2016; Lamb et al, 2012; Lin et al, 2016; Maida et al, 2017; Mangin et al, 1998; Mostarda et al, 2009; Pereira‐Junior et al, 2010; Powell et al, 2021; Ramaekers et al, 2002; Ribeiro et al, 2021; Saalfield & Spear, 2014; Scridon et al, 2012; Shi et al, 2017; Simoes et al, 2016; Zajączkowski et al, 2018).…”
Section: Hrv: Control (Baseline) Values From Frequency‐domain Analysismentioning
confidence: 99%
“…We hypothesized that gradually released aliskiren from polymer-based nanoparticles could at least partially solve the problem of bioavailability and frequency of the treatment. Therefore, we used a lower dose of aliskiren (25 mg/kg/day) in our experiment than is usual in other studies [16,17].…”
Section: Introductionmentioning
confidence: 99%